SHMT1 and neoplasm: Future analysis will be needed to fully elucidate the structural features of the non-canonical RNA-binding domain of SHMT1, as well as of its complexes with RNA, and to assess the effectiveness in the cells of novel nucleic acid-based inhibitors of the SHMT enzyme, which represents an attractive target for novel metabolic anti-tumour chemotherapy.